Issues
-
Cover Image
Cover Image
Of the more than 270,000 breast cancers and 57,000 pancreatic cancers diagnosed annually, approximately 10-15% are hereditary and are associated with a germline pathogenic variant or likely pathogenic variant (PV) in a hereditary cancer risk gene. The ATM (ataxia telangiectasia mutated) gene is located on chromosome 11q22.3 and is comprised of 66 exons that code a 350.6 kDa protein involved in various cellular activities, including DNA double-strand break repair through its activity as a phosphorylase of key proteins involved in response to DNA damage. While the recessively inherited childhood disease Ataxia Telangiectasia requires two (homozygous) ATM PVs to manifest disease and is rare in the population, approximately 1 in 300 individuals carry one (heterozygous) ATM PV. In the study starting on page 433, Hall and colleagues examine the cancer risks in heterozygous ATM PV carriers using a large database of over 600,000 individuals tested with a multi-gene panel for hereditary cancer risk. Elevated risks for several cancers including breast, pancreatic, prostate, and gastric among others were identified in ATM PV carriers. The cover image shows the exons of the human ATM, as well as the PV location on the gene, frequency as represented by the height of the line at each location on the gene, and variant type represented by the color of the line, for the 4,607 ATM PVs identified in the study population. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Review
Research Brief
Research Articles
Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility
Obesity is Associated with Shorter Telomere Length in Prostate Stromal Cells in Men with Aggressive Prostate Cancer
A Retrospective Chart Review of Children in Neurocutaneous Clinic Who May Benefit from Further Evaluation Beyond Neurofibromatosis Type I
This study suggests that at-risk population with a suspected NF1 diagnosis may benefit from further evaluation. Correct diagnosis of constitutional mismatch repair deficiency is crucial to diagnose cancer at an early stage or prevent cancer from occurring.
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.